ProNoxis

What ProNoxis does

ProNoxis AB is a Swedish preclinical pharmaceutical R&D company founded in 2009 as a spin-off from Redoxis AB, headquartered in Trollhättan, Sweden with 1-10 employees. The company develops small-molecule agonists of Formyl-peptide receptor 1 (FPR1) that activate the NADPH oxidase 2 (NOX2) complex, a mechanism intended to modulate innate immune responses for the treatment of chronic inflammatory, autoimmune, and infectious diseases. Its lead compound, RE-04-001, demonstrates selective FPR1 agonism with an EC50 of approximately 1 nM, and the portfolio includes biased FPR1 agonists with structural differentiation from competitor molecules; preclinical proof-of-concept data show disease amelioration in relevant in vivo models.

ProNoxis owns all IP rights generated jointly with Redoxis since 2009 in the NADPH/NOX2 activation field. In February 2024, founder Dr. Peter Olofsson-Sahl (via Inexius AB) acquired full ownership from Redoxis. In October 2024, the company transferred all intellectual property rights and its small molecule library to a newly created spin-off, Inicure AB in Gothenburg, which is dedicated to advancing FPR1 agonists for infectious diseases and antimicrobial resistance. Through 2025, ProNoxis has continued operations as an affiliated third party in the EU-funded Neutrocure program (2020-2025, EUR 3,000,000 total budget) and secured an EIC Booster grant to support R&D validation and commercial maturity activities at Inicure, with chemistry lead optimization support from ScilifeLAB.

The company has no commercial products, no disclosed revenue, and no commercial pricing; its business model centers on grant-funded discovery research (Vinnova, Eurostars, EU-FET, EIC) and the pursuit of co-development partnerships and licensing agreements with academic and industrial counterparties. The customer base consists of research collaborators rather than paying customers, and the principal customers of the underlying technology are pharmaceutical or biotech partners that may license or co-develop the FPR1 agonist platform in the future.

Name

ProNoxis

Legal name

Pronoxis AB

Website

https://pronoxis.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

ProNoxis AB is a Swedish preclinical pharmaceutical company developing small-molecule FPR1 agonists that activate the NOX2 complex to treat inflammatory, autoimmune, and infectious diseases, operating through grant-funded research and co-development partnerships with academic and industry collaborators.

Ownership category

akta.pro rank

Product category

Preclinical Anti-Inflammatory Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Small molecule therapeutics
• FPR1 agonists
• NOX2 activators
• Anti-inflammatory drugs
• Autoimmune disease research

Headquarters

HQ city

Göteborg

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Co-development and Joint Ventures: ProNoxis seeks joint ventures and collaborations with partners to apply their proprietary compounds for further preclinical and clinical development, potentially generating revenue through partnership agreements, milestone payments, and licensing deals.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

ProNoxis AB is a preclinical-stage biopharmaceutical company developing small-molecule agonists of the FPR1/NOX2 (NADPH oxidase) pathway for the treatment of chronic inflammatory, autoimmune, and infectious diseases. The company's lead compound RE-04-001 is a selective FPR1 agonist (EC50 approximately 1 nM) designed to activate the NOX2 complex. ProNoxis operates through co-development partnerships, licensing arrangements, and EU-funded research collaborations rather than commercial product sales.

Product overview

ProNoxis is a preclinical-stage pharmaceutical company developing a single lead compound (RE-04-001) — a selective small-molecule FPR1 agonist targeting the NADPH oxidase 2 (NOX2) complex — for treatment of chronic inflammatory, autoimmune, and infectious diseases. The company does not offer a platform or multiple commercial products; its portfolio consists of proprietary biased FPR1 agonists at various stages of preclinical research and validation.

Differentiator

Problem solved

Functional benefit

Products and services

• RE-04-001 Lead Compound

Quantifiable outcome

• EC50 approximately 1 nM for FPR1 activation
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Neutrocure (EU-FET Program)coreStrategic or Co-development Partner · 9 October 2019EU-funded FET Open Horizon 2020 project focused on development of smart amplifiers of reactive oxygen species for treatment of inflammatory/autoimmune diseases, cancer and myeloablation. Collaboration with academic groups in Germany, UK, Ukraine, Spain and France, running 2020-2025 with total budget approximately EUR 3,000,000.
• Swansea UniversitycoreStrategic or Co-development PartnerAcademic research partner in the Neutrocure project, collaborating on exploring the role of ProNoxis compounds in inflammation and infections.
• Friedrich-Alexander University Erlangen-NuernbergcoreStrategic or Co-development PartnerAcademic research partner in the Neutrocure project focusing on preclinical research in redox regulation of the immune system.
• Nationwide Children's HospitalminorStrategic or Co-development PartnerResearch collaboration with the Kidney and Urinary Tract Research Center in Columbus, Ohio, jointly studying NOX inhibition for treatment of kidney and urinary tract diseases, and exploring anti-bacterial properties of FPR-specific agonists for urinary tract infections.
• Inicure ABcoreStrategic or Co-development PartnerSpin-off company established October 1, 2024 by Peter Olofsson-Sahl, Sara Malcus, and Johan Bylynd. Received all IPR rights, small molecule library, and project results from ProNoxis. Dedicated to developing FPR1 agonists for treatment of infectious diseases including antimicrobial resistance, supported by Gothenburg University incubator.
• Gothenburg University Incubator (GU Ventures)minorStrategic or Co-development PartnerUniversity incubator that supported establishment of spin-off company Inicure AB.
• Redoxis ABcoreStrategic or Co-development PartnerOriginal parent company (CRO) from which ProNoxis was spun off in 2009. Collaboration continued during 2012-2019 for discovery research. In February 2024, sold all shares in ProNoxis to Inexius AB. ProNoxis continues as affiliated third party in Neutrocure project.
• ScilifeLABminorStrategic or Co-development PartnerSwedish national core facility providing support for chemistry lead optimisation as part of BOOST-iCURE project and EIC-Booster grant activities.

Scale indicators3 records

Recent moves9 records

Expansion highlights4 records

Broad incumbents

• MorphoSys AG: European biopharma with autoimmune/inflammation commercial assets (e.g., Tremfya-related collaborations) and a history of high-value M&A (acquired by Novartis in 2024). Relevant comparable for European autoimmune-focused biotech value trajectories and partnership outcomes.
• Argenx SE: Late-stage commercial biotech with FcRn inhibitor Vyvgart in autoimmune disease (gMG, CIDP). Comparable as a European-listed autoimmune-inflammation leader that illustrates the value-creation trajectory available to differentiated mechanism players in this space.
• AbbVie Inc. Global leader in autoimmune disease (Humira, Skyrizi, Rinvoq) and the dominant incumbent in inflammatory indications ProNoxis targets. Most relevant broad incumbent for assessing competitive intensity, partnership appetite, and M&A benchmarks in the autoimmune space.
• Galapagos NV: European biotech with a deep inflammation/autoimmune pipeline (e.g., JAK1, TYK2 programs). Comparable as a mid-cap European inflammation specialist with similar discovery-to-partnership business model and EU regulatory exposure.

Emerging players

• Annexon, Inc. Clinical-stage immunology company modulating the complement/inflammation cascade; relevant because it is an emerging clinical player targeting classical and alternative inflammatory pathways with similar deal-making interest from big pharma in autoimmune indications.
• Dice Therapeutics (acquired by Eli Lilly): Preclinical-to-clinical biotech developing oral small-molecule IL-17 inhibitors for autoimmune diseases, acquired by Eli Lilly in 2023. Directly comparable as a small-molecule autoimmune player that achieved a major pharma exit at early-clinical stage — a relevant reference for ProNoxis's path.

Direct peers

• Inicure AB: Spin-off founded by ProNoxis's CEO in October 2024 that received all of ProNoxis's FPR1/NOX2 IP and small molecule library; dedicated to FPR1 agonists for severe infections and antimicrobial resistance — the most direct comparable company by mechanism, indication, and founding team.
• Cyxone AB: Swedish preclinical/early-clinical biotech developing small-molecule therapies for autoimmune and inflammatory diseases (notably rheumatoid arthritis and MS). Highly comparable by geography, therapeutic focus, company size, and small-molecule approach to inflammatory/autoimmune disease.

Others

• Redoxis AB: Former parent company of ProNoxis and original co-developer of the NADPH/NOX2 program since 2009. Comparable as an adjacent CRO/research-services player in the same redox-immunology mechanistic area, though no longer a direct drug-development competitor after selling ProNoxis to Inexius AB in 2024.

Regional players

• BioInvent International AB: Swedish clinical-stage biotech developing immune-modulatory antibodies for cancer and autoimmune disease. Comparable as a Sweden-headquartered immunology biotech with similar grant/equity funding mix and academic/industrial partnership model, useful for regional financing comparables.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProNoxis